相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cost-effectiveness analysis of multigene expression profiling assays to guide adjuvant therapy decisions in women with invasive early-stage breast cancer
Malek B. Hannouf et al.
PHARMACOGENOMICS JOURNAL (2020)
Cost-effectiveness Analysis of CYP2D6*10 Pharmacogenetic Testing to Guide the Adjuvant Endocrine Therapy for Postmenopausal Women with Estrogen Receptor Positive Early Breast Cancer in China
Xiaoxia Wei et al.
CLINICAL DRUG INVESTIGATION (2020)
Interrogation of CYP2D6 Structural Variant Alleles Improves the Correlation Between CYP2D6 Genotype and CYP2D6-Mediated Metabolic Activity
Rachel Dalton et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2020)
Genomic Ancestry, CYP2D6, CYP2C9, and CYP2C19 Among Latin Americans
Fernanda Rodrigues-Soares et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
The Influences of Adherence to Tamoxifen and CYP2D6 Pharmacogenetics on Plasma Concentrations of the Active Metabolite (Z)-Endoxifen in Breast Cancer
Jeanine Marie Nardin et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2020)
High content phenotypic screening identifies serotonin receptor modulators with selective activity upon breast cancer cell cycle and cytokine signaling pathways
Scott J. Warchal et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2020)
CYP2D6*10 pharmacogenetic-guided SERM could be a cost-effective strategy in Chinese patients with hormone receptor-positive breast cancer
Xiaoxia Wei et al.
PHARMACOGENOMICS (2020)
Endocrine Therapy Nonadherence and Discontinuation in Black and White Women
Stephanie B. Wheeler et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
Endocrine Therapy Nonadherence and Discontinuation in Black and White Women
Stephanie B. Wheeler et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM Study
Anabel Sanchez-Spitman et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Pharmacogenomic-pharmacokinetic study of selective estrogen-receptor modulators with intra-patient dose escalation in breast cancer
Hiroshi Ishiguro et al.
BREAST CANCER (2019)
Association of CYP2D6*10 (c. 100 C>T) Genotype with Z-END Concentration in Patients with Breast Cancer Receiving Tamoxifen Therapy in Indonesian Population
Yenny et al.
ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS (2019)
Impact of Curcumin (with or without Piperine) on the Pharmacokinetics of Tamoxifen
Koen G. A. M. Hussaarts et al.
CANCERS (2019)
4-Hydroxytamoxifen enhances sensitivity of estrogen receptor -positive breast cancer to docetaxel in an estrogen and ZNF423 SNP-dependent fashion
Gen Wang et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen
A. B. Sanchez-Spitman et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2019)
Genomics education in nursing in Hong Kong, Taiwan and Mainland China
Sek Ying Chair et al.
INTERNATIONAL NURSING REVIEW (2019)
Pharmacogenomics, CYP2D6, and Tamoxifen: A Survey of the Reasons Sustaining European Clinical Practice Paradigms
Sara S. Reis et al.
MEDICINA-LITHUANIA (2019)
Non-CYP2D6 Variants Selected by a GWAS Improve the Prediction of Impaired Tamoxifen Metabolism in Patients with Breast Cancer
Ewa E. Hennig et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Tamoxifen Pharmacogenetics and Metabolism: The Same Is Not the Same
Hiltrud Brauch et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Plasma endoxifen and 4-hydroxytamoxifen levels in CYP2D6(C100T) carrying breast cancer patients and association with serum cholesterol
Ta-Chung Chao et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2019)
CYP2D6 Genotype Predicts Plasma Concentrations of Tamoxifen Metabolites in Ethiopian Breast Cancer Patients
Jemal Hussien Ahmed et al.
CANCERS (2019)
Targeting DNA methylation for treating triple-negative breast cancer
Jia Yu et al.
PHARMACOGENOMICS (2019)
Pharmacogenomics research and clinical implementation in Brazil
Fernanda Rodrigues-Soares et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2019)
CYP2D6-inhibiting medication use and inherited CYP2D6 variation in relation to adverse breast cancer outcomes after tamoxifen therapy
Sophie E. Mayer et al.
CANCER CAUSES & CONTROL (2019)
Impact of CYP2D6 polymorphisms on endoxifen concentrations and breast cancer outcomes
G. S. Hwang et al.
PHARMACOGENOMICS JOURNAL (2018)
Comparison of Drug Metabolism and Its Related Hepatotoxic Effects in HepaRG, Cryopreserved Human Hepatocytes, and HepG2 Cell Cultures
Yuichi Yokoyama et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2018)
Analyzing the clinical actionability of germline pharmacogenomic findings in oncolog
Rebecca Wellmann et al.
CANCER (2018)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy
Matthew P. Goetz et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
The Underrated Risks of Tamoxifen Drug Interactions
Philip D. Hansten
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS (2018)
Novel Strategies on Personalized Medicine for Breast Cancer Treatment: An Update
Carmen W. H. Chan et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
The effect of CYP2D6*10 polymorphism on adjuvant tamoxifen in Asian breast cancer patients: a meta-analysis
Junjun Lu et al.
ONCOTARGETS AND THERAPY (2017)
Application of Mice Humanized for CYP2D6 to the Study of Tamoxifen Metabolism and Drug-Drug Interaction with Antidepressants
A. Kenneth MacLeod et al.
DRUG METABOLISM AND DISPOSITION (2017)
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems
J. A. Luzum et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
Lyndsay N. Harris et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
CYP2D6 gene polymorphisms in Brazilian patients with breast cancer treated with adjuvant tamoxifen and its association with disease recurrence
Mariella De Ameida Melo et al.
BIOMEDICAL REPORTS (2016)
Rifampin-Mediated Induction of Tamoxifen Metabolism in a Humanized PXR-CAR-CYP3A4/3A7-CYP2D6 Mouse Model
Jae H. Chang et al.
DRUG METABOLISM AND DISPOSITION (2016)
Boronic prodrug of 4-hydroxytamoxifen is more efficacious than tamoxifen with enhanced bioavailability independent of CYP2D6 status
Qiu Zhong et al.
BMC CANCER (2015)
Boronic prodrug of endoxifen as an effective hormone therapy for breast cancer
Changde Zhang et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
Individualization of tamoxifen therapy: Much more than just CYP2D6 genotyping
Lisette Binkhorst et al.
CANCER TREATMENT REVIEWS (2015)
No effect on pharmacokinetics of tamoxifen and 4-hydroxytamoxifen by multiple doses of red clover capsule in rats
Kanumuri Siva Rama Raju et al.
SCIENTIFIC REPORTS (2015)
Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: Implications for Germline Pharmacogenetic Studies
Matthew P. Goetz et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Determination of CYP2D6*3,*4, and*10 frequency in women with breast cancer in Sao Luis, Brazil, and its association with prognostic factors and disease-free survival
D. M. F. Martins et al.
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH (2014)
CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations
M. A. Province et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations
Adrian LLerena et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2014)
Efficacy and tolerability of toremifene and tamoxifen therapy in premenopausal patients with operable breast cancer: a retrospective analysis
T. Qin et al.
CURRENT ONCOLOGY (2013)
The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents
Wenjie Jessie Lu et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Metabolic Activity in the Insular Cortex and Hypothalamus Predicts Hot Flashes: An FDG-PET Study
Hadine Joffe et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Differences in genotype and allele frequency distributions of polymorphic drug metabolizing enzymes CYP2C19 and CYP2D6 in mainland Chinese Mongolian, Hui and Han populations
S. -J. Yin et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2012)
Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy
Alastair M. Thompson et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network
M. V. Relling et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Should CYP2D6 inhibitors be administered in conjunction with tamoxifen?
Hitoshi Zembutsu et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2011)
Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen
Werner Schroth et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients
J. M. Rae et al.
PHARMACOGENOMICS JOURNAL (2009)
Tamoxifen pharmacogenomics: The role of CYP2D6 as a predictor of drug response
M. P. Goetz et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes
Werner Schroth et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment
Y Jin et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Retinoblastoma: Revisiting the model prototype of inherited cancer
DR Lohmann et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART C-SEMINARS IN MEDICAL GENETICS (2004)
分享论文
